Joshua Grass, John Kelly, and Lauren Daniel Join 5AM VenturesEnhancing the depth of 5AM’s operational & scientific expertise
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
